Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Lymphoma Drug Fails In Late-Stage Trial-Reuters


Friday, 10 May 2013 10:14am EDT 

Reuters reported that Eli Lilly And Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma. The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following chemotherapy treatment. Lymphoma is a cancer of the lymphatic system. 

Company Quote

51.75
0.467 +0.91%
11:42am EDT